Luis M. Branco, Ph.D., has extensive expertise in multiple facets of research and development of chimeric, humanized, human, and affinity maturation of recombinant antibodies for human use. During 22 years in industry he was directly involved in the development of licensed antibody therapeutics, such as MedImmune’s Synagis (Palivizumab), Human Genome Sciences’ Benlysta (Belimumab) and ABthrax (raxibacumab), as well as additional antibodies under clinical evaluation (MEDI’s Numax [motavizumab], HGS’ CCR5mAb004, HGS-ETR1 [Mapatumumab].
Dr. Branco is the inventor of a novel mammalian cell-based biomanufacturing system for production of regulatory-compliant recombinant proteins . He is a co-founder of BioFactura, a biotech company in the Washington-D.C. area dedicated to development of therapeutics for Biodefense. Since 2008 Dr. Branco has been actively directing R&D aspects of the Viral Hemorrhagic Fever Consortium’s Lassa fever program. In 2011 Drs. Branco and Robert F. Garry of Tulane University co-founded Zalgen Labs to advance the development of antibody-based therapeutics for Lassa fever and other viral hemorrhagic fevers, and development of rapid diagnostic testing platforms for Lassa, Ebola and Marburg viruses.
The pre-clinical evaluation toward IND of a first-in-class human antibody-based immunotherapeutic - Arevirumab-3 - for the treatment of Lassa fever is a top tier priority for Dr. Branco, Zalgen Labs, and the VHFC. The therapeutic cocktail has demonstrated remarkable efficacy in resolving advanced Lassa fever in nonhuman primates. The marketing by Zalgen and the VHFC of a suite of immunodiagnostics for the detection of active Lassa fever and the measurement of antibody responses to viral infection are the culmination of multi-disciplinary and international collaboration in the fight against this high impact disease.
research & development
Interested in learning more about this Devex member?
With a Recruitment Account, you can view the full profile & CV for this member and other professionals around the world. Click here to know more!